Wall Street brokerages predict that China Biologic Products, Inc. (NASDAQ:CBPO) will report earnings per share (EPS) of $1.36 for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $1.10 during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.6%. The company is scheduled to issue its next earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that China Biologic Products will report full year earnings of $4.85 per share for the current year. For the next year, analysts expect that the company will post earnings of $5.95 per share, with EPS estimates ranging from $5.88 to $6.02. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow China Biologic Products.

Several brokerages have weighed in on CBPO. Goldman Sachs Group, Inc. (The) began coverage on China Biologic Products in a report on Tuesday, May 30th. They set a “neutral” rating for the company. Zacks Investment Research lowered China Biologic Products from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $140.00 price objective on shares of China Biologic Products in a report on Monday, June 12th.

China Biologic Products (NASDAQ:CBPO) traded down 0.21% during mid-day trading on Thursday, reaching $102.67. The company had a trading volume of 103,460 shares. China Biologic Products has a one year low of $96.99 and a one year high of $137.38. The stock has a market capitalization of $2.79 billion, a PE ratio of 26.59 and a beta of 1.74. The company’s 50-day moving average is $111.44 and its 200-day moving average is $109.44.

In other news, insider Zhijing Cbpo Liu sold 7,500 shares of the firm’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $116.49, for a total value of $873,675.00. Following the completion of the transaction, the insider now directly owns 10,969 shares of the company’s stock, valued at $1,277,778.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.73% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. UBS Asset Management Americas Inc. raised its position in China Biologic Products by 9.3% in the first quarter. UBS Asset Management Americas Inc. now owns 198,220 shares of the biopharmaceutical company’s stock worth $19,848,000 after buying an additional 16,933 shares during the last quarter. Pictet Asset Management Ltd. bought a new position in China Biologic Products during the first quarter worth approximately $1,762,000. Bank of New York Mellon Corp raised its position in China Biologic Products by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 563,527 shares of the biopharmaceutical company’s stock worth $56,426,000 after buying an additional 31,297 shares during the last quarter. Henderson Group PLC raised its position in China Biologic Products by 9.3% in the first quarter. Henderson Group PLC now owns 188,585 shares of the biopharmaceutical company’s stock worth $18,877,000 after buying an additional 16,017 shares during the last quarter. Finally, First Trust Advisors LP raised its position in China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares during the last quarter. 74.28% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “China Biologic Products, Inc. (NASDAQ:CBPO) Expected to Post Earnings of $1.36 Per Share” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/13/china-biologic-products-inc-nasdaqcbpo-expected-to-post-earnings-of-1-36-per-share.html.

China Biologic Products Company Profile

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.